CHICAGO (EGMN) - The investigational drug axitinib prolonged median progression-free survival by 2 months, compared with sorafenib, in a randomized, phase III trial that was conducted in patients with metastatic renal cell carcinoma resistant to initial therapy.The international 723-patient AXIS (Axitinib [AG 013736] for the Treatment of Metastatic Renal Cell Cancer) trial was the first to compare targeted second-line therapies in this or any setting, according to lead author Dr. Brian I. Rini of...